相关实验视频

Updated: Jul 13, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

CUDC-101是EGFR过度表达膀癌细胞的潜在向抑制剂

Zhenxing Wang¹, Lanxin Li¹, Chunhong Chu²

¹Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan 475000, P.R. China.

International journal of oncology

|October 13, 2023

概括

多位抑制剂CUDC-101显示出治疗膀癌的巨大潜力. 它有效地减少了癌细胞的增殖,并诱导EGFR过度表达细胞的亡.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

膀癌是一种普遍存在的尿道恶性瘤,具有复杂的分子基础.
致癌与细胞增殖和亡抵抗性有关,通常涉及皮肤外生长因子受体 (EGFR) 和受体氨酸蛋白激酶ErbB-2信号传递.
针对性治疗对于管理EGFR驱动的膀癌至关重要.

研究的目的:

研究多位抑制剂CUDC-101在EGFR过度表达的膀癌细胞中的治疗潜力.
评估膀癌细胞系对CUDC-101.1的化学敏感性.
阐明CUDC-101发挥抗癌作用的机制.

主要方法:

构建具有EGFR过度表达的T24膀癌细胞系.
应用化学敏感性测试来评估CUDC-101的疗效.
分析细胞形态,微纤维结构,细胞周期进展和亡诱导.

主要成果:

CUDC-101对膀癌细胞表现出剂量依赖的细胞毒性作用.
抑制剂显著抑制了生长活力和增殖.
CUDC-101诱导了形态变化,阻止了细胞循环的进展,并促进了细胞亡.

结论:

CUDC-101在过度表达EGFR的膀癌细胞中显示出强大的细胞毒性和抗增殖作用.
该药物有效地抑制细胞分裂并诱导细胞亡,支持其抗癌活性.
CUDC-101代表了治疗膀癌的有希望的候选药物,特别是在EGFR过度表达的情况下.

关键词:

在 CUDC‐101 中,CUDC‐101 是一个 CUDC.欧洲农业基金会 (EGFR) 是一个.膀癌:膀癌是一种癌症.细胞毒理学细胞毒理学它们的扩散和扩散.

更多相关视频

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...